Información del artículo
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Collins F.S., McKusick V.A..
Implications of the Human Genome Project for medical science.
JAMA, 285 (2001), pp. 540-544
[2.]
Staudt L.M., Brown P.O..
Genomic views of the immune system.
Annu Rev Immunol, 18 (2000), pp. 829-859
[3.]
Subramanian G., Adams M.D., Venter J.C., Broder S..
Implications of the human genome for understanding human biology and medicine.
JAMA, 286 (2001), pp. 2296-2307
[4.]
Huston J.S., George A.J..
Engineered antibodies take center stage.
Hum Antibodies, 10 (2001), pp. 127-142
[5.]
Koths K..
Recombinant proteins for medicaluse: the attractions and challenges.
Curr Opin Biotech, 6 (1995), pp. 681-687
[6.]
Thomas S.M..
Genomics: the implications for ethics and education.
Br Med Bull, 55 (1999), pp. 429-445
[7.]
Wierda D., Smith H.W., Zwickl C.M..
Immunogenicity of biopharmaceuticals in laboratory animals.
Toxicology, 158 (2001), pp. 71-74
[8.]
Schellekens H..
Bioequivalence and the immunogenicity of biopharmaceuticals.
Nat Rev Drug Discov, 1 (2002), pp. 457-462
[9.]
Porter S..
Human immune response to recombinant human proteins.
Pharma Sci, 90 (2000), pp. 1-11
[10.]
Janeway C.A., Travers P., Walport M., Capra J.D..
Immunobiology: The immune system in health and disease, 4ª, pp. 33-76
[11.]
Gurunathan S., Klinman D.M., Seder R.A..
DNA vaccines: immunology, application, andoptimization.
Annu Rev Immunol, 18 (2000), pp. 927-974
[12.]
Richards S..
Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders, 2 (2002), pp. 241-253
[13.]
Grauer A., Frank-Raue K., Schroth J., Raue F., Ziegler R..
Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease.
Dtsch Med Wochenschr, 119 (1994), pp. 507-510
[14.]
Chafee S., Mary A., Stiehm E.R., Girault D., Fischer A., Hershfield M.S..
IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
J Clin Invest, 89 (1992), pp. 1643-1651
[15.]
Dummer R., Muller W., Nestle F., Wiede J., Dues J., Lechner W., et al.
Formation of neutralizing antibodies against natural interferon-β, but not against recombinant interferon-γ during adjuvant therapy for high-risk malignant melanoma.
Cancer, 67 (1991), pp. 2300-2304
[16.]
Frasier S.D..
Human pituitary growth hormone (hGH) therapy in growth hormone deficiency.
Endocr Rev, 4 (1983), pp. 155-170
[17.]
Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al.
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Eng J Med, 7 (2002), pp. 469-475
[18.]
Konstsek P., Liptakova H., Kontsekova E..
Immunogenicity of interferon-α2 in therapy: structural and physiological aspects.
Acta Virol, 43 (1999), pp. 63-70
[19.]
Benjamin D.C., Berzofsky J.A., East I.J., Gurd F.R.N., Hannum C., Leach S.J., et al.
The antigenic structure of proteins: a reappraisal.
Annu Rev Immunol, 2 (1984), pp. 67-101
[20.]
Harlow E., Lane D..
Antibodies: a laboratory manual.
Cold Spring Harbor, (1988), pp. 53-137
[21.]
Benz I., Schmidtz A..
Never say never again:protein glycosilation in pathogenic bacteria.
Mol Microbiol, 45 (2002), pp. 267-276
[22.]
Levine J.S., Branch D.W., Rauch J..
The antiphospholipid syndrome.
N Eng J Med, 346 (2002), pp. 752-763
[23.]
Hahn B.V..
Antibodies to DNA.
N Eng J Med, 338 (1998), pp. 1359-1368
[24.]
Nakra P., Manivel V., Vishwakarma R.A., Rao K.V..
B cell responses to a peptide epitope X. Epitope selection in a primary response is thermodynamically regulated.
J Immunol, 164 (2000), pp. 5615-5625
[25.]
Davidson A., Diamond B..
Autoimmune diseases.
N Eng J Med, 345 (2001), pp. 340-350
[26.]
Vyse T.J., Kotzin B.L..
Genetic susceptibility to systemic lupus erythematosus.
Annu Rev Immunol, 16 (1998), pp. 261-292
[27.]
Klein J., Sato A..
The HLA system: first of two parts.
N Eng J Med, 343 (2000), pp. 702-709
[28.]
Prabhakar S.S., Muhlfelder T..
Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
Clin Nephrol, 47 (1997), pp. 331-335
[29.]
Kamradt T., Mitchinson N.A..
Tolerance and autoimmunity.
N Eng J Med, 344 (2001), pp. 655-664
[30.]
Martinez-Taboada V., Bartolome M.J., Amado J.A., Blanco R., Garcia-Unzueta M.T., Rodriguez-Valverde V., et al.
Changes in peripheral blood lymphocyte subsets in elderly subjects are associated with an impaired function of the hypothalamic-pituitary-adrenal axis.
Mech Ageing Dev, 123 (2002), pp. 1477-1486
[31.]
Buttgereit F., Burmester G.R., Brand M.D..
Bioenergetics of immune functions: fundamental and therapeutic aspects.
Immunol Today, 21 (2000), pp. 192-199
[32.]
Arnaiz A., Perez-Blas M., Subiza J.L..
Artal PInmunopatología, 1ª, pp. 435-445
[33.]
Warren H.S., Vogel F.R., Chedid L.A..
Current status of immunological adjuvants.
Annu Rev Immunol, 4 (1986), pp. 369-388
[34.]
Wucherpfennig K.W..
Mechanism for the induction of autoimmunity by infectious agents.
J Clin Invest, 108 (2001), pp. 1097-1104
[35.]
Torres B.A., Jonson H.M..
Modulation of disease by superantigens.
Curr Opin Immunol, 10 (1998), pp. 465-470
[36.]
Benoist C., Mathis D..
Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?.
Nat Immunol, 2 (2001), pp. 797-801
[37.]
DiPaolo B., Pennetti A., Nugent L., Venkat K..
Monitoring impurities in biopharmaceuticals produced by recombinant technology.
Pharm Sci Technol Today, 2 (1999), pp. 70-82
[38.]
Wang W..
Lyophilization and development of solid protein pharmaceuticals.
Int J Pharm, 203 (2000), pp. 1-60
[39.]
Waterman K.C., Adami R.C., Alsante K.M., Hong J., Landis M.S., Lombardo F., et al.
Stabilization of pharmaceuticals to oxidative degradation.
Pharm Dev Technol, 7 (2002), pp. 1-32
[40.]
Podda A..
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
Vaccine, 19 (2001), pp. 2673-2680
[41.]
Weiner H.L..
Oral tolerance: immune mechanisms and treatment of autoimmune diseases.
Immunol Today, 18 (1997), pp. 335-343
[42.]
Delves P.J., Roitt I.M..
The immune system: first of two parts.
N Eng J Med, 343 (2000), pp. 37-49
Copyright © 2004. Academia de Ciencias Médicas de Bilbao